Knight Therapeutics Inc. (TSX:GUD)

Market Cap	606.20M
Revenue (ttm)	371.30M
Net Income (ttm)	4.33M
Shares Out	99.54M
EPS (ttm)	0.04
PE Ratio	152.25
Forward PE	117.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,012
Average Volume	44,679
Open	6.05
Previous Close	6.08
Day's Range	6.05 - 6.15
52-Week Range	5.09 - 6.45
Beta	0.17
RSI	59.45
Earnings Date	May 8, 2025

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD